blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3347047

EP3347047 - EXPRESSION VECTOR DELIVERY SYSTEM AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  30.03.2019
Database last updated on 02.09.2024
FormerRequest for examination was made
Status updated on  15.06.2018
FormerThe international publication has been made
Status updated on  21.03.2017
Formerunknown
Status updated on  19.12.2016
Most recent event   Tooltip27.09.2023New entry: Renewal fee paid 
Applicant(s)For all designated states
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
National Institutes of Health
Office of Technology Transfer
6011 Executive Boulevard
Suite 325, MSC 7660
Bethesda, MD 20852-7660 / US
For all designated states
The Chancellor, Masters and Scholars of The University of Oxford
University Offices
Wellington Square
Oxford, Oxfordshire OX1 2JD / GB
[2018/29]
Inventor(s)01 / SEDER, Robert
Building 40 40 Convent Drive
Bethesda, MD 20814 / US
02 / LYNN, Geoffrey
Building 40 40 Convent Drive
Bethesda, MD 20814 / US
03 / SEYMOUR, Leonard
University Offices
Wellington Square
Oxford OX1 2JD / GB
 [2018/29]
Representative(s)Forresters IP LLP
Skygarden
Erika-Mann-Straße 11
80636 München / DE
[N/P]
Former [2018/29]Gowshall, Jonathan Vallance
Forresters IP LLP
Skygarden
Erika-Mann-Strasse 11
80636 München / DE
Application number, filing date16775023.109.09.2016
[2018/29]
WO2016US51037
Priority number, dateUS201562215927P09.09.2015         Original published format: US 201562215927 P
[2018/29]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017044803
Date:16.03.2017
Language:EN
[2017/11]
Type: A1 Application with search report 
No.:EP3347047
Date:18.07.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 16.03.2017 takes the place of the publication of the European patent application.
[2018/29]
Search report(s)International search report - published on:EP16.03.2017
ClassificationIPC:A61K39/39
[2018/29]
CPC:
A61K39/39 (EP,US); A61K47/59 (US); A61K47/6455 (US);
A61K47/65 (US); A61K48/0041 (US); A61K2039/53 (EP,US);
A61K2039/55511 (EP,US); A61K2039/55555 (EP,US); A61K2039/6093 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/29]
TitleGerman:EXPRESSIONSVEKTOR-ABGABESYSTEM UND DESSEN VERWENDUNG ZUR INDUZIERUNG EINER IMMUNANTWORT[2018/29]
English:EXPRESSION VECTOR DELIVERY SYSTEM AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE[2018/29]
French:SYSTÈME D'ADMINISTRATION DE VECTEURS D'EXPRESSION ET UTILISATION DE CE DERNIER POUR INDUIRE UNE RÉPONSE IMMUNITAIRE[2018/29]
Entry into regional phase19.03.2018National basic fee paid 
19.03.2018Designation fee(s) paid 
19.03.2018Examination fee paid 
Examination procedure19.03.2018Examination requested  [2018/29]
19.03.2018Date on which the examining division has become responsible
14.11.2018Amendment by applicant (claims and/or description)
03.04.2019Despatch of a communication from the examining division (Time limit: M06)
14.10.2019Reply to a communication from the examining division
23.01.2020Despatch of a communication from the examining division (Time limit: M04)
02.06.2020Reply to a communication from the examining division
19.10.2020Despatch of a communication from the examining division (Time limit: M06)
28.04.2021Reply to a communication from the examining division
Fees paidRenewal fee
01.04.2018Renewal fee patent year 03
27.09.2019Renewal fee patent year 04
28.09.2020Renewal fee patent year 05
27.09.2021Renewal fee patent year 06
27.09.2022Renewal fee patent year 07
27.09.2023Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XI]WO2010128303  (HYBRID BIOSYSTEMS LTD [GB], et al) [X] 1,3,4,7,11,14-18,23-27,30-34,39-42,44,45,47-51 * page 2, line 16 - line 21 * * page 3, line 5 - line 25 * * page 5, line 11 - page 6, line 12 * * page 9, line 8 - line 24 * * page 16, line 27 - page 17, line 19 * * page 18, line 27 - page 19, line 14 * * page 20, line 5 - line 21; example - * [I] 2,5,6,8-10,12,13,19-22,28,29,35-38,43,46,52-55;
 [A]US2015037326  (BUTLER-RANSOHOFF JOHN-EDWARD [DE], et al) [A] 1-51 * page 1, paragraph 0001 * * page 2, paragraph 0023 * * page 3, paragraph 0033 * * page 11, paragraph 88 - paragraph 92 * * page 19, paragraph 164 - page 20, paragraph 167 * * page 27, paragraph 264 * * page 28, paragraph 270 - page 29, paragraph 276 * * page 30, paragraph 296 * * page 32, paragraph 316 - paragraph 317 * * page 35, paragraph 334 - paragraph 343 * * page 36, paragraph 361 - paragraph 365; example - *;
 [A]  - STONE GEOFFREY W ET AL, "Nanoparticle-Delivered Multimeric Soluble CD40L DNA Combined with Toll-Like Receptor Agonists as a Treatment for Melanoma", PLOS ONE, (200910), vol. 4, no. 10, ISSN 1932-6203, XP002765245 [A] 1-55 * page 2, column l, paragraph 2 * * page 2, column r, paragraph l - page 5, paragraph 1 * * page 8, column r, paragraph 2 - page 10 *
 [A]  - OH Y-K ET AL, "Enhanced adjuvanticity of interleukin-2 plasmid DNA administered in polyethylenimine complexes", VACCINE, ELSEVIER, AMSTERDAM, NL, (20030620), vol. 21, no. 21-22, doi:10.1016/S0264-410X(03)00178-6, ISSN 0264-410X, pages 2837 - 2843, XP004429682 [A] 1-51 * page 2837, column r, paragraph l - page 2838, column l, paragraph 2 * * page 2840, column l, paragraph 2 - page 2842, column r, paragraph l *

DOI:   http://dx.doi.org/10.1016/S0264-410X(03)00178-6
 [I]  - NIKUNJ M. SHUKLA ET AL, "Structure-Activity Relationships in Human Toll-Like Receptor 7-Active Imidazoquinoline Analogues", JOURNAL OF MEDICINAL CHEMISTRY, (20100610), vol. 53, no. 11, doi:10.1021/jm100358c, ISSN 0022-2623, pages 4450 - 4465, XP055081984 [I] 52-55 * the whole document *

DOI:   http://dx.doi.org/10.1021/jm100358c
by applicantUS4501729
 US4652441
 US4675189
 US4677191
 US4689338
 US4728721
 US4880935
 US4917893
 US5122368
 US5622929
 US5824805
 US6214345
 US6518265
 US8323696
    - WALES ET AL., BIOCHEM SOC TRANS., (2007), vol. 35, pages 1501 - 1503
    - Remington's Pharmaceutical Sciences, MACK PUBLISHING CO.
    - BERGE ET AL., J. PHARM. SCI., (1977), vol. 66, page 1
    - BITTER ET AL., METHODS IN ENZYMOLOGY, (1987), vol. 153, pages 516 - 544
    - SHMUELI ET AL., J. VISUALIZED EXP., (2013), vol. 73, page E50176
    - GUERRERO CAZAREZ ET AL., ACS NANO, (2014), vol. 8, pages 5141 - 5153
    - DUBOWCHIK; WALKER, PHARM. THERAPEUTICS, (1999), vol. 83, pages 67 - 123
    - NEVILLE ET AL., BIOL. CHEM., (1989), vol. 264, pages 14653 - 14661
    - THORPE ET AL., CANCER RES., (1987), vol. 47, pages 5924 - 5931
    - PHILLIPS ET AL., CANCER RES., (2008), vol. 68, page 92809290
    - JOHNSON ET AL., ANTICANCER RES., (1995), vol. 15, pages 1387 - 1393
    - LAU ET AL., BIOORG-MED-CHEM., (1995), vol. 3, no. 10, pages 1299 - 1304
    - LAU ET AL., BIOORG-MED-CHEM., (1995), vol. 3, no. 10, pages 1305 - 1312
    - BAROUCH ET AL., J. VIROL, (2005), vol. 79, pages 8828 - 8834
    - AUSUBEL ET AL., Current Protocols in Molecular Biology, JOHN WILEY & SONS, (2013), vol. 104
    - FORDE ET AL., MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, (2014), vol. 1, page 14012
    - LEE ET AL., HUM VACCIN IMMUNOTHER., (2015), vol. 11, no. 8, pages 1889 - 1900
    - CZARNIECKI, M. ET AL., J. MED. CHEM, (2008), vol. 51, pages 6621 - 6626
    - GERSTER, J., F. ET AL., J. MED. CHEM, (2005), vol. 48, pages 3481 - 3491
    - SINGH, M. ET AL., J. IMMUNOLOGY, (2014), vol. 193, pages 4722 - 4731
    - BERGE ET AL., J. PHANN. SCI., (1977), vol. 66, page 1
    - MICHAEL ET AL., J. PHARMACY PHARMACOL., (1991), vol. 43, pages 1 - 5
    - GONDA, CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, (1990), vol. 6, pages 273 - 313
    - RAEBURN ET AL., J. PHARMACOL. TOXICOL. METH., (1992), vol. 27, page 143
    - TOPALIAN ET AL., J CLIN ONCOL, (2011), vol. 29, pages 4828 - 4836
    - ARANDA ET AL., ONCOIMMUNOLOGY, (2013), vol. 2, page E26621
    - YADAV ET AL., NATURE, (2014), vol. 515, pages 572 - 576
    - SHUKLA ET AL., J MED CHEM, (2010), vol. 53, pages 4450 - 4465
    - GERSTER ET AL., J MED CHEM, (2005), vol. 48, pages 3481 - 3491
    - RYU ET AL., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, (2014), vol. 136, pages 10823 - 10825
    - SHUKLA ET AL., BIOORG MED CHEM LETT, (2010), vol. 20, pages 6384 - 6386
    - SHUKL ET AL., J MED CHEM, (2010), vol. 53, pages 4450 - 4465
    - SHUKLA E, J MED CHEM, (2010), vol. 53, pages 4450 - 4465
    - LEBLEU ET AL., CHEM. COMMUN., (2014), vol. 50, pages 1836 - 1838
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.